Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-VWF Recombinant Antibody (1A11) (CBMAB-V0148-YC)


See all VWF antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
1A11
Antibody Isotype
IgG2a, к
Application
ELISA, WB

Basic Information

Immunogen
VWF (aa H22258.1, aa 1-273) full-length human protein. Immunogen sequence: MGAQDEEEGI QDLDGLLVFD KIVEVTLLNL PWYNEETEGQ RGEMTAPKSP RAKIRGTLCA EGTRGRSSTA RCSLFGSDFV NTFDGSMYSF AGYCSYLLAG GCQKRSFSII GDFQNGKRVS LSVYLGEFFD IHLFVNGTVT QGDQRVSMPY ASKGLYLETE AGYYKLSGEA YGFVARIDGS GNFQVLLSDR YFNKTCGLCG NFNIFAEDDF MTQEGTLTSD PYDFANSWAL SSGEQWCERA SPPSSSCNIS SGEMQKVGVD WPGCTWMVCD FWI
Specificity
Human
Antibody Isotype
IgG2a, к
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
aa 1-273

Target

Full Name
Von Willebrand Factor
Introduction
VWF is a glycoprotein involved in hemostasis. VWF is proteolytically processed following assembly into large multimeric complexes. These complexes function in the adhesion of platelets to sites of vascular injury and the transport of various proteins in the blood. Mutations in VWF result in von Willebrand disease, an inherited bleeding disorder.
Entrez Gene ID
7450
UniProt ID
P04275
Alternative Names
Von Willebrand Factor; F8VWF; Coagulation Factor VIII VWF; VWD; VWF
Function
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Biological Process
Biological Process blood coagulation Source:UniProtKB1 Publication
Biological Process cell adhesion Source:UniProtKB1 Publication
Biological Process cell-substrate adhesion Source:UniProtKB1 Publication
Biological Process hemostasis Source:UniProtKB1 Publication
Biological Process platelet activation Source:UniProtKB1 Publication
Biological Process positive regulation of intracellular signal transduction Source:ARUK-UCL1 Publication
Biological Process response to wounding Source:UniProtKB1 Publication
Cellular Location
Secreted
Secreted, extracellular space, extracellular matrix
Localized to storage granules.
Involvement in disease
von Willebrand disease 1 (VWD1):
A common hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 1 is characterized by partial quantitative deficiency of circulating von Willebrand factor, that is otherwise structurally and functionally normal. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma.
von Willebrand disease 2 (VWD2):
A hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in altered platelet aggregation. Von Willebrand disease type 2 is characterized by qualitative deficiency and functional anomalies of von Willebrand factor. It is divided in different subtypes including 2A, 2B, 2M and 2N (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M are defective in their platelet-dependent function, whereas the mutant protein in type 2N is defective in its ability to bind factor VIII. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma.
von Willebrand disease 3 (VWD3):
A severe hemorrhagic disorder due to a total or near total absence of von Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. Bleeding usually starts in infancy and can include epistaxis, recurrent mucocutaneous bleeding, excessive bleeding after minor trauma, and hemarthroses.
PTM
All cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
More Infomation
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-VWF Recombinant Antibody (1A11)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry